Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

Inclusion Criteria

• •Patients must have histologically or cytologically documented salivary gland cancers; patients that do not have a salivary gland primary must have one of the following histologies - adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma
• •Patients must have recurrent and/or metastatic disease that is progressive and not amenable to surgery or curative radiotherapy occurring within 6 months of study entry, as evidenced by: at least a 20% increase in radiographically or clinically measurable disease, appearance of any new lesions, or deterioration in clinical status
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• •Patients with measurable disease per RECIST 1.1 criteria
• •* At least one lesion of \>= 1.5 cm in long-axis diameter for non lymph nodes or \>= 1.5 cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST 1.1 using either computerized tomography (CT) or magnetic resonance imaging (MRI)
• •* Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST 1.1 to be deemed a target lesion
• •Absolute neutrophil count \>= 1,500/μL
• •Platelets \>= 100,000/μL
• •Creatinine clearance \>= 40 mL/min
• •Bilirubin =\< 1.5 upper limit of normal (ULN)
• •Alkaline phosphatase =\< 3 ULN; if total ALP is \> 3 x ULN (in the absence of liver metastasis) or \> 5 x ULN in subjects with liver metastasis AND the subject is known to have bone metastases, then liver ALP iso-enzyme should be used to assess liver function rather than total ALP
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 X ULN
• •Women of child-bearing potential (WOCP) and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation
• •Life expectancy of \> 12 weeks
• •Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment